Helpful tool or blunt instrument?-the European Association of Urology Biochemical Recurrence Risk Classification as a decision-making tool for salvage radiotherapy.
作者信息
Correa Rohann J M, Mendez Lucas C
机构信息
Department of Radiation Oncology, London Health Sciences Centre, London, Canada.
出版信息
Transl Androl Urol. 2024 May 31;13(5):889-892. doi: 10.21037/tau-23-665. Epub 2024 May 17.
Abstract
摘要
相似文献
1
Helpful tool or blunt instrument?-the European Association of Urology Biochemical Recurrence Risk Classification as a decision-making tool for salvage radiotherapy.
Transl Androl Urol. 2024 May 31;13(5):889-892. doi: 10.21037/tau-23-665. Epub 2024 May 17.
2
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2024 Feb;85(2):164-170. doi: 10.1016/j.eururo.2023.05.038. Epub 2023 Jun 22.
3
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):32-39. doi: 10.1111/bju.15762. Epub 2022 Jul 12.
4
External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort.
Eur Urol. 2019 Jun;75(6):896-900. doi: 10.1016/j.eururo.2019.03.016. Epub 2019 Apr 5.
5
Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
Eur Urol Focus. 2024 Jan;10(1):66-74. doi: 10.1016/j.euf.2023.07.004. Epub 2023 Jul 26.
6
The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.
Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.
7
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
BJU Int. 2024 Feb;133 Suppl 3:39-47. doi: 10.1111/bju.16158. Epub 2023 Sep 14.
8
Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer.
Int J Clin Oncol. 2019 Oct;24(10):1238-1246. doi: 10.1007/s10147-019-01463-5. Epub 2019 May 13.
9
Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
Eur Urol Oncol. 2018 Sep;1(4):276-282. doi: 10.1016/j.euo.2018.04.014. Epub 2018 Sep 28.
10
Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
Int Braz J Urol. 2019 Mar-Apr;45(2):237-245. doi: 10.1590/S1677-5538.IBJU.2018.0039.
本文引用的文献
1
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
2
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2024 Feb;85(2):164-170. doi: 10.1016/j.eururo.2023.05.038. Epub 2023 Jun 22.
3
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
JAMA Netw Open. 2023 May 1;6(5):e2314748. doi: 10.1001/jamanetworkopen.2023.14748.
4
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
J Clin Oncol. 2023 Jun 10;41(17):3217-3224. doi: 10.1200/JCO.22.02389. Epub 2023 Apr 27.
5
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):32-39. doi: 10.1111/bju.15762. Epub 2022 Jul 12.
6
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Eur Urol Oncol. 2022 Jun;5(3):304-313. doi: 10.1016/j.euo.2021.04.011. Epub 2021 May 18.
7
F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
Lancet. 2021 May 22;397(10288):1895-1904. doi: 10.1016/S0140-6736(21)00581-X. Epub 2021 May 7.
8
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
JAMA Oncol. 2021 Apr 1;7(4):544-552. doi: 10.1001/jamaoncol.2020.7671.
9
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14.
10
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17.
Zotero 插件